Trial Profile
A retrospective study assessing the safety and efficacy of Immune checkpoint inhibitors in the treatment of various cancers among people living with HIV
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Jul 2022
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Avelumab (Primary) ; Durvalumab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Anal cancer; Cancer; Head and neck cancer; Kaposi's sarcoma; Liver cancer; Non-small cell lung cancer; Small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 11 Jul 2022 New trial record
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology